Información del autor
Documentos disponibles escritos por este autor (2)
Añadir el resultado a su cesta Hacer una sugerencia Refinar búsqueda
texto impreso
Sharma, S. ; Gralla, J. ; Ordonez, J. G. ; Hurtado, M. E. ; Swenson, E. R. ; Schoene, R. B. ; Kelly, J. P. ; Callacondo, D. ; Rivard, C. ; Roncal-Jimenez, C. ; Sirota, J. ; Fuquay, R. ; Jackson, B. P. ; Swenson, K. E. ; Johnson, R. J. ; Hurtado, A. ; Escudero, E. | Elsevier | 2019-01-25T16:36:30ZPatients suffering from chronic mountain sickness (CMS) have excessive erythrocytosis. Low level cobalt toxicity as a likely contributor has been demonstrated in some subjects. We performed a randomized, placebo controlled clinical trial in Cerr[...]texto impreso
Wheeler, D.C. ; Stefansson, B.V. ; Batiushin, M. ; Bilchenko, O. ; Cherney, D.Z.I. ; Chertow, G.M. ; Douthat, W. ; Dwyer, J.P. ; Escudero, E. ; Pecoits-Filho, R. ; Furuland, H. ; Górriz, J.L. ; Greene, T. ; Haller, H. ; Hou, F.F. ; Kang, S.-W. ; Isidto, R. ; Khullar, D. ; Mark, P.B. ; McMurray, J.J.V. ; Kashihara, N. ; Nowicki, M. ; Persson, F. ; Correa-Rotter, R. ; Rossing, P. ; Toto, R.D. ; Umanath, K. ; Van Bui, P. ; Wittmann, I. ; Lindberg, M. ; Sjöström, C.D. ; Langkilde, A.M. ; Heerspink, H.J.L. | NLM (Medline) | 2020-12-14T16:11:09ZBACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardi[...]
